Circ-ATAD1 is overexpressed in osteosarcoma (OS) and suppresses the maturation of miR-154-5p to increase cell invasion and migration

Jihui Zhou¹, Li Xu², Peng Yang³, Shibang Lin¹* and Haizhou Huang¹

Abstract

Background: Circ-ATAD1 plays an oncogenic role in gastric cancer. However, its roles in other cancers are unclear. We aimed to analyze the role of circ-ATAD1 in osteosarcoma (OS).

Methods: The expression levels of circ-ATAD1, mature miR-154-5p, and premature miR-154-5p in paired OS and non-tumor tissues from 56 OS patients were determined using RT-qPCR. Nuclear fractionation assay was performed to analyze the subcellular location of circ-ATAD1. The interaction between circ-ATAD1 and premature miR-154-5p was analyzed using RNA pull-down assay. The role of circ-ATAD1 in regulating miR-154-5p maturation was analyzed using RT-qPCR in cells with overexpression. Transwell assays were performed to analyze the roles of circ-ATAD1 and miR-154-5p in regulating OS cell invasion and migration.

Results: Circ-ATAD1 was overexpressed in OS compared to non-tumor tissues and was detected in the nuclei of OS cells. Mature miR-154-5p, but not premature miR-154-5p, was downregulated in OS tissues compared to non-tumor tissues and was inversely correlated with circ-ATAD1. In OS cells, circ-ATAD1 overexpression decreased the expression of mature miR-154-5p, but not premature miR-154-5p. Transwell assay analysis showed that circ-ATAD1 overexpression increased cell invasion and migration, and mature miR-154-5p overexpression suppressed these cell behaviors. In addition, circ-ATAD1 overexpression reduced the effects of mature miR-154-5p overexpression on cell behaviors.

Conclusions: Circ-ATAD1 is overexpressed in OS and suppresses miR-154-5p maturation to increase cell invasion and migration.

Keywords: Osteosarcoma, Circ-ATAD1, miR-154-5p, Maturation, Migration, Invasion

Introduction

Osteosarcoma (OS), also refers to osteogenic sarcoma, is the most common type of bone malignancies [1]. OS mainly affects young adults, teenagers, and children [2, 3]. It is estimated that OS affects about 4.4 out of 1 million people younger than 25 years, with a lower incidence in whites than in blacks [2, 3]. OS patients diagnosed at early stages can usually be cured after combined therapies, including surgical resection, radiotherapy, and chemotherapy [4]. However, distant tumor metastasis is frequently observed by the time of initial diagnosis of OS [5]. In addition, postoperative recurrence is also common [6], leading to poor survival. Therefore, treatment of OS still requires the development of novel approaches.
With the advantages of fewer adverse effects and high efficiency, molecular targeted therapy, which can be applied to regulate cancer-related gene expression, has shown potentials in the treatment of cancers, including OS [7–10]. For instance, insulin-like growth factor-2 receptor has been proven to be a potential target to treat OS [8]. However, more molecular targets are needed to further improve OS-targeted therapy. Circular RNAs (circRNAs) have no or limited coding capacity, but they affect cancer development mainly by regulating the expression of protein-coding genes [11, 12], suggesting that circRNAs are potential targets for cancer therapy. Circ-ATAD1 has been reported to play an oncogenic role in gastric cancer [13]. Our preliminary microarray data have shown that circ-ATAD1 expression is altered in OS and inversely correlated with miR-154-5p to which suppresses OS [14]. Based on our knowledge, the cross-talk between circ-ATAD1 and miR-154-5p has not been reported previously. Therefore, we analyzed the interaction between circ-ATAD1 and miR-154-5p in OS.

Materials and methods

Paired tissue samples

No circ-ATAD1 expression data were found in public datasets, such as TCGA. Therefore, to analyze the differential expression of circ-ATAD1, this study included 56 OS patients who were willing to donate tissue samples. All patients were enrolled at Maoming People’s Hospital after the Ethics Committee of this hospital approved this study. The 56 patients included 30 males and 26 females, with a mean age of 19.9 ± 4.7 years. All patients and their patients signed informed consent. Surgical resection was performed on these patients. Tumors were dissected by experienced histopathologists to separate tumor tissues (OS) and normal bone tissues at the edge of tumors (non-tumor). Based on pathological analysis, the 56 patients included 38 cases at AICC stage I or II and 18 cases at stage III or IV. Patients complicated with other severe clinical disorders or subjected to treatments prior to admission were excluded.

OS cells and transfections

Two OS cell lines, Hs 3.T and MG-63, and normal bone cell line Hfob1.19 (ATCC, USA) were used in this study. Cell culture was carried out following the manufacturer’s instructions. Circ-ATAD1 and miR-154-5p overexpression and circ-ATAD1 silencing were reached in Hs 3.T and MG-63 cells by transfecting pcDNA3.1-circ-ATAD1 expression vector, mimic of miR-154-5p, or circ-ATAD1 siRNA (Ribobio) using Neon Transfection.
System (Thermo Fisher Scientific). All operations were performed following the manufacturer’s instructions. Overexpression was confirmed by RT-qPCR every 24 h until 72 h or 96 h. Empty vector or miRNA mimic were included as the negative controls. Un-transfected cells were used as controls.

RNA sample preparation
Total RNAs were extracted from cells from each transfection group and paired tissues from each patient using Ribozol reagent (Invitrogen) and treated with DNase I (Sangon) to remove genomic DNAs until an OD 260/280 ratio close to 2.0 was reached. RNA integrity was analyzed by separating RNAs on 5% urea-PAGE gels.

RT-qPCRs
To determine circ-ATAD1 and premature miR-154-5p expression in cells and tissues, RNA samples were first reverse transcribed into cDNA samples and analyzed using qPCRs with 18S rRNA as the internal control. Mature miR-154-5p expression in RNA samples was analyzed using All-in-One™ miRNA qRT-PCR Detection Kit (Genecopoeia). Ct values were processed using the $2^{-\Delta\Delta C_t}$ method.

Nuclear fractionation assay
Circ-ATAD1 subcellular localization in Hs 3.T and MG-63 cells was analyzed using a Nuclear/Cytosol Fractionation Kit (BioVision, # K266). Briefly, cells were fractionated into nuclear and cytoplasm samples and subjected to total RNA extraction followed by RT-PCR.
to determine circ-ATAD1 expression with GAPDH as the internal control.

**RNA pull-down assay**

Premature miR-154-5p and mimic miRNA (no targets in the human genome) were labeled with biotin and named bio-pre-miR-154-5p and bio-mimic miRNA, respectively. Hs 3.T and MG-63 cells were transfected with bio-pre-miR-154-5p or bio-mimic miRNA, and the biotinylated miRNAs were isolated using streptavidin magnetic beads (Invitrogen). Circ-ATAD1 levels in these two pull-down samples were detected using RT-qPCRs.

**Cell invasion and migration assay**

The invasion and migration abilities of both Hs 3.T and MG-63 cells were analyzed using Transwell inserts (8 μm, Corning). Prior to invasion assay, insert membranes were coated with Matrigel (Corning) for 8 h. Briefly, cells in non-serum media were added to the upper chamber, and cell invasion and migration were induced for 24 h by media with 20% FBS to the lower chamber. The migrating and invading cells were stained using 0.5% crystal violet (Sigma-Aldrich) and observed and counted under a microscope.

**Results**

Levels of circ-ATAD1 and mature miR-154-5p, but not premature miR-154-5p, were altered in OS

The levels of circ-ATAD1, mature miR-154-5p, and premature miR-154-5p in paired OS and non-tumor tissues from 56 OS patients were determined by RT-qPCR. Circ-ATAD1 is overexpressed (Fig. 1A, \( p < 0.01 \)), while mature miR-154-5p was under-expressed in OS tissues (Fig. 1B, \( p < 0.01 \)) than in non-tumor tissues. In contrast, premature miR-154-5p level was not significantly altered (Fig. 1C). The levels of circ-ATAD1, mature miR-154-5p, and premature miR-154-5p in normal bone cell line HØb1.19 and OS cell lines Hs 3.T and MG-63 were also analyzed using RT-qPCR. Compared to HØb1.19 cells, Hs 3.T and MG-63 cells exhibited significantly increased circ-ATAD1 (Fig. 1D, \( p < 0.01 \)) and decreased mature miR-154-5p (Fig. 1E, \( p < 0.01 \)) levels. No significant difference in premature miR-154-5p level was observed among the three cell lines.
Circ-ATAD1 was inversely correlated with mature miR-154-5p, but not premature miR-154-5p

Pearson's correlation coefficient analysis showed that circ-ATAD1 levels were inversely and significantly correlated with mature miR-154-5p levels across OS tissues (Fig. 2A). In contrast, circ-ATAD1 and mature miR-154-5p were not significantly correlated with each other (Fig. 2B).

Circ-ATAD1 is expressed in both the nucleus and cytoplasm and directly interacts with premature miR-154-5p

Nuclear fractionation assay was performed to analyze the subcellular location of circ-ATAD1 in both Hs 3.T and MG-63 cells. It was observed that circ-ATAD1 was expressed in both nuclei and cytoplasm of these cells (Fig. 3A). RNA pull-down assay was performed to analyze the interaction between circ-ATAD1 and premature miR-154-5p. Compared to miRNA mimic group, bio-pre-miR-154-5p group showed significantly higher circ-ATAD1 level (Fig. 3B, *p < 0.001).

Circ-ATAD1 overexpression suppressed miR-154-5p maturation in Hs 3.T and MG-63 cells

Hs 3.T and MG-63 cells were transfected with circ-ATAD1 expression vector or miR-154-5p mimic. It was observed that circ-ATAD1 and miR-154-5p were significantly overexpressed between 24 and 72 h compared to control (C) and NC (pcDNA3.1 or NC miRNA) groups (Fig. 4A, *p < 0.01 or **p < 0.001). Moreover, circ-ATAD1 overexpression decreased mature miR-154-5p level (Fig. 4B, *p < 0.05, or **p < 0.001), but not premature miR-154-5p level (Fig. 4C). Moreover, no significant changes in circ-ATAD1 expression level were observed

Fig. 5  Circ-ATAD1 overexpression increased miR-154-5p level in Hs 3.T and MG-63 cells. SiRNA silencing of circ-ATAD1 was achieved from 24 to 96 h in Hs 3.T and MG-63 cells (A). Circ-ATAD1 silencing increased mature miR-154-5p level (B). *, p < 0.05; **, p < 0.01; ***, p < 0.001
in cells with miR-154-5p overexpression at each time point (Fig. 4D). SiRNA silencing of circ-ATAD1 was also achieved from 24 to 96 h (Fig. 5A, \( p < 0.05 \), \( p < 0.01 \) or \( p < 0.001 \)). It was observed that circ-ATAD1 silencing increased mature miR-154-5p level (Fig. 5B, \( p < 0.01 \) or \( p < 0.001 \)). PIWIL1 is a confirmed target of miR-154-5p [14]. It was observed that circ-ATAD1 overexpression increased PIWIL1 mRNA level (Additional file 1: Fig. S1, \( p < 0.01 \) or \( p < 0.001 \)).
Circ-ATAD1 increased the invasion and migration of both Hs 3.7 and MG-63 cells via miR-154-5p

Transwell assays were performed to analyze the roles of circ-ATAD1 and miR-154-5p in regulating OS cell invasion and migration. Our data illustrated that circ-ATAD1 overexpression increased cell invasion (Fig. 6A, p < 0.05 or p < 0.01) and migration (Fig. 6B, p < 0.05 or p < 0.01) compared to C and NC groups, and mature miR-154-5p overexpression suppressed cell behaviors. In addition, circ-ATAD1 overexpression reduced the effects of mature miR-154-5p overexpression on cell behaviors.

Discussion

This study explored the interaction between circ-ATAD1 and miR-154-5p in OS and showed that circ-ATAD1 was highly expressed in OS and might inhibit miR-154-5p maturation to attenuate its tumor-suppressive role in OS.

Zhang et al. recently characterized a novel oncogenic circRNA named circ-ATAD1 in gastric cancer [13] and demonstrated that circ-ATAD1 was highly expressed in gastric cancer. In addition, circ-ATAD1 might sponge miR-140-3p to increase YY1 expression. YY1 then binds to PCIF1 promoter to upregulate PCIF1 and promote gastric cancer progression [13]. Based on our knowledge, the function of circ-ATAD1 in other cancers is unknown. In this study, we observed circ-ATAD1 upregulation in OS. In addition, circ-ATAD1 overexpression increased the invasion and migration of two GC cell lines. Therefore, circ-ATAD1 is likely an oncogenic circRNA in GC.

MiR-154-5p plays different roles in different cancers [14–16]. For instance, miR-154-5p is highly expressed in renal cell carcinoma and plays its oncogenic roles by inhibiting cell apoptosis and increasing cell proliferation [15]. In contrast, miR-154-5p was under-expressed in glioblastoma. MiR-154-5p overexpression targets PIWIL1 to suppress cell metastasis and proliferation, suggesting it plays a tumor-suppressive role [16]. Tian et al. reported miR-154-5p downregulation in OS [14]. In addition, miR-154-5p overexpression suppresses OS progression by upregulating Bax and cleaved caspase 3 and downregulating Bcl-2 [14]. Our study confirmed miR-154-5p downregulation in OS and further showed the inhibitory effects of miR-154-5p on OS cell invasion and migration.

Although miR-154-5p has been proven to play critical roles in different cancers [14–16], its upstream regulators in these cancers are unknown. In this study, we showed that circ-ATAD1 could suppress miR-154-5p maturation in OS cells. We also showed that circ-ATAD1 could be detected in both nuclei and cytoplasm. In addition, circ-ATAD1 could directly interact with premature miR-154-5p. Considering the fact that the movement of premature miRNAs from the nucleus to the cytoplasm is essential for miRNA maturation [17], we speculated circ-ATAD1 might suppress the transportation of premature miR-154-5p by directly suppressing its maturation.

Although numerous studies have been performed to explore the roles of ncRNAs in human diseases [18–21], more efforts should be made to further analyze their potentials in disease treatment.

Conclusion

Circ-ATAD1 is overexpressed in OS and might sponge miR-154-5p to suppress OS cell invasion and migration.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13018-021-02809-4.

Additional file 1. Figure S1. Circ-ATAD1 overexpression increased PIWIL1 mRNA level. The role of circ-ATAD1 in the expression of PIWIL1, a confirmed target of miR-154-5p, was analyzed with RT-qPCR. **, p<0.01; ***, p<0.001.

Acknowledgements

This work was supported by the High-level Hospital Construction Research Project of Maoming People’s Hospital.

Authors’ contributions

JZ and SL contributed to study concepts, literature research, clinical studies, data analysis, experimental studies, manuscript writing and review; LX contributed to study design, literature research, experimental studies and manuscript editing; PY contributed to definition of intellectual content, clinical studies, data acquisition and statistical analysis; HH contributed to data acquisition, manuscript preparation and data analysis. All authors have read and approved the submission of the manuscript.

Funding

Not Applicable.

Availability of data and materials

The data are not publicly available due to their containing information that could compromise the privacy of research participants, but are available on reasonable request from the corresponding author.

Declarations

Ethical approval and consent to participate

All patients and their patients signed informed consent. All procedures were approved by the Ethics Committee of Maoming People’s Hospital and operated in keeping with the standards set out in the Announcement of Helsinki and Laboratory Guidelines of Research in China.

Consent for publication

Not applicable.

Competing interests

All authors declare that they do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.

Author details

1Department of Traumatic Orthopedics, Maoming People’s Hospital, No. 101 Wemin Road, Maoming City 525000, Guangdong Province, People’s Republic of China. 2The 9th Recuperation Department of Qingdao Special Service-men Recuperation Center of PLA NAVY, Qingdao City 266071, Shandong
Province, People’s Republic of China. 3 Department of Hand and Foot Surgery, The Eighth People’s Hospital of Qingdao, Qingdao City 266100, Shandong Province, People’s Republic of China.

Received: 5 August 2021 Accepted: 24 October 2021 Published online: 02 December 2021

References
1. Durfee RA, Mohammed M, Luu HH. Review of osteosarcoma and current management. Rheumatol Therapy. 2016;3(2):221–43.
2. Nie Z, Peng H. Osteosarcoma in patients below 25 years of age: an observational study of incidence, metastasis, treatment and outcomes. Oncol Lett. 2018;16(5):6502–14.
3. Moreno F, Cacciavilliano W, Cipolla M, Corini M, Streitenberger P, López Martí J, et al. Childhood osteosarcoma: Incidence and survival in Argentina. Report from the National Pediatric Cancer Registry, ROHA Network 2000–2013. Pediatric Blood Cancer. 2017; 64(10).
4. Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol Offic J Am Soc Clin Oncol. 2015;33(27):3029–35.
5. Lindsey BA, Markel JE, Kleinerman ES. Osteosarcoma overview. Rheumatol Therapy. 2017;4(1):25–43.
6. Dav NC, Chou AJ, Jaffe N, Rao BN, Billups CA, Rodriguez-Galindo C, et al. Recurrent osteosarcoma with a single pulmonary metastasis: a multi-institutional review. Br J Cancer. 2015;112(2):278–82.
7. Baudino TA. Targeted cancer therapy: the next generation of cancer treatment. Curr Drug Discov Technol. 2015;12(1):3–20.
8. Chaiyawat P, Settakorn J, Sangsin A, Teeyakasem P, Klangjorhor J, Soongkhaw A, et al. Exploring targeted therapy of osteosarcoma using proteomics data. Onco Targets Ther. 2017;10:565–77.
9. Geller DS, Morris J, Revskaya E, Kahn M, Zhang W, Piperdi S, et al. Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R). Nucl Med Biol. 2016;43(12):812–7.
10. Wang Y, Zhou Y, Hu Z. The functions of circulating tumor cells in early diagnosis and surveillance during cancer advancement. J Transl Int Med. 2017;5:135-138. https://doi.org/10.1515/jtim-2017-0029.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more: biomedcentral.com/submissions